ライフサイエンスコーパス: clinical specimen

1 cter cloacae strain, M12X01451, from a human clinical specimen.

2 t the HCC-PDX model was derived from the HCC clinical specimen.

3 y after initial isolation of bacteria from a clinical specimen.

4 al MAOA-induced Twist1/IL-6/STAT3 pathway in clinical specimens.

5 dult inpatients with S. aureus isolated from clinical specimens.

6 and small cell lung cancer (SCLC) lines and clinical specimens.

7 es with Snail level in cancer cell lines and clinical specimens.

8 R assay regarding 464 pathogens found in the clinical specimens.

9 ly with disease recurrence and metastasis in clinical specimens.

10 ly detect a variety of pathogens directly in clinical specimens.

11 further optimized for detecting PEDV RNA in clinical specimens.

12 so successfully applied to detecting PEDV in clinical specimens.

13 ed multiple organisms in 81 (5.86%) positive clinical specimens.

14 ependent manner both in RCC cell culture and clinical specimens.

15 apid detection of mycobacteria directly from clinical specimens.

16 y the panel in 1,382 (88.1%) of the positive clinical specimens.

17 not well understood due to limited access to clinical specimens.

18 Bipolaris spp.) was also identified in other clinical specimens.

19 ilable laboratory methods to identify VRE in clinical specimens.

20 ay expedite the identification of E. coli in clinical specimens.

21 drug targets and downstream substrates using clinical specimens.

22 ral use in reversing formaldehyde adducts in clinical specimens.

23 eatment, and detection of mixed infection in clinical specimens.

24 especially viral, are often scarce in human clinical specimens.

25 en CD117 or ZEB1 and DAB2IP is also found in clinical specimens.

26 viscosity and inactivated M. tuberculosis in clinical specimens.

27 outine microbiologic culture were applied to clinical specimens.

28 molecular detection of meningococcal DNA in clinical specimens.

29 tection of human enterovirus D68 (EV-D68) in clinical specimens.

30 ing sufficient, highly pure genomic DNA from clinical specimens.

31 validated in BRAF inhibitor-resistant NSCLC clinical specimens.

32 rapid method for detecting M. pneumoniae in clinical specimens.

33 uantifying specific proteins and peptides in clinical specimens.

34 ed in cellular models matched the pattern of clinical specimens.

35 able/nonviable isolates and culture-negative clinical specimens.

36 ssive high-throughput screening for NSCLC in clinical specimens.

37 ns present at >2% of the viral population in clinical specimens.

38 on of intratumoral genetic heterogeneity for clinical specimens.

39 de rapid detection of respiratory viruses in clinical specimens.

40 , and F. tularensis is seldom recovered from clinical specimens.

41 ntire genome sequences from small amounts of clinical specimens.

42 erobic Gram-positive organisms isolated from clinical specimens.

43 ility of the assay target region from >2,100 clinical specimens.

44 4 x 10(-6) in cell lines and 2.6 x 10(-5) in clinical specimens.

45 ectrometry to identify pathogens directly in clinical specimens.

46 g the identification of yeasts isolated from clinical specimens.

47 within the 95% prediction intervals for the clinical specimens.

48 formalin-fixed and paraffin-embedded (FFPE) clinical specimens.

49 SIRT1 and also confirmed NRF2 activation in clinical specimens.

50 he growth and identification of viruses from clinical specimens.

51 valuate antibodies and other biomolecules in clinical specimens.

52 termined using 48 reference isolates and 254 clinical specimens.

53 e routine detection of viral nucleic acid in clinical specimens.

54 -regulated in prostate cancer cell lines and clinical specimens.

55 he detection of SARS-CoV-2 nucleic acid from clinical specimens.

56 D Viper LT platform using both contrived and clinical specimens.

57 test for C. auris infection from culture and clinical specimens.

58 for detection of M. pneumoniae directly from clinical specimens.

59 on of developing cortical tissue in infected clinical specimens.

60 cordance between GATA2 and miR-194 levels in clinical specimens.

61 e obtained from ALK, ROS1 and RET FISH on 51 clinical specimens.

62 asma further encouraged assay application on clinical specimens.

63 was developed to detect HIV-1 p24 antigen in clinical specimens.

64 robeads are employed for DNA extraction from clinical specimens.

65 er bereziniae originally isolated from human clinical specimens.

66 per 10 000 hospital admissions had positive clinical specimens.

67 In clinical specimens, a genetic signature comprising four

68 In 90 colorectal cancer clinical specimens, a significant positive correlation w

69 Clinical specimen analysis revealed that reduced express

70 Evaluation of 21 clinical specimens and 115 clinical isolates demonstrate

71 rategy for the detection of acanthamoebae in clinical specimens and are likely to be more practical t

72 ly with Akt phosphorylation in breast cancer clinical specimens and cell lines.

73 ent HAdV types were detected in three of the clinical specimens and confirmed by amplicon sequencing.

74 tform for analyzing protein glycosylation in clinical specimens and could complement the existing too

75 relevant to other contexts in which residual clinical specimens and data are used for research purpos

76 (kappa >/= 0.89) for the detection of CMV in clinical specimens and demonstrated increased sensitivit

77 he Enterobacteriaceae family in a variety of clinical specimens and diagnostic contexts.

78 Clinical specimens and food samples were tested for botu

79 This observation was further validated with clinical specimens and functionally verified using demet

80 ecificity to detect and differentiate HSV in clinical specimens and identified 57 additional specimen

81 cytes, as well as in colon tumors from human clinical specimens and intestinal tumors from Apc(Min/+)

82 , and larval identification was attempted on clinical specimens and meat samples.

83 hroconis olivacea and Ochroconis ramosa from clinical specimens and Ochroconis icarus of an environme

84 etection and subtyping of influenza virus in clinical specimens and offers significant advantages ove

85 By studying lung adenocarcinoma clinical specimens and preclinical models, our computati

86 Accuracy was evaluated for 109 selected clinical specimens and revealed an average sensitivity a

87 The parallels between pathologies present in clinical specimens and the highly tractable three-dimens

88 d clear parallels between the pathologies of clinical specimens and virus-infected organoids, demonst

89 tection of Neisseria gonorrhoeae only from a clinical specimen, and controls were individuals with a

90 MITF protein levels vary between and within clinical specimens, and amplifications and gain- and los

91 isolates, including 15 recovered from human clinical specimens, and found that they clustered with t

92 ontrols for direct patient care, handling of clinical specimens, and managing regulated medical waste

93 Analyses in human cells, clinical specimens, and mouse models demonstrated that R

94 grating electronic health records, discarded clinical specimens, and proteomics identified 2 biomarke

95 ion and identification of bacterial DNA from clinical specimens are a foundational approach in the pr

96 lecular methods with improved sensitivity on clinical specimens are being developed but are not yet r

97 e in biomedical research, particularly where clinical specimens are not available in amounts amenable

98 has inherent limitations for the analysis of clinical specimens as there are often substantial variat

99 A total of 343 clinical specimens as well as 29 external quality assess

100 Importantly, high nuclear TIAM1 in clinical specimens associates with increased CRC patient

101 e lung cancer cells, mouse models, and human clinical specimens before the onset of acquired drug res

102 Clinical specimens (blood, cerebrospinal fluid, and urin

103 ibraries prepared directly from a variety of clinical specimens (blood, urine, breast milk, respirato

104 In clinical specimens, brain metastases have elevated HIF1A

105 Many studies of glycans rely on clinical specimens, but the low amount of sample availab

106 r versatility is well established for modern clinical specimens, but they have yet to be applied to a

107 al composition of challenging, heterogeneous clinical specimens by deep sequencing, culture-based str

108 c variations were identified in fresh frozen clinical specimens by Illumina RNA-sequencing, the STAR

109 general challenges of pathogen detection in clinical specimens by metagenomic sequencing, the advant

110 We further demonstrated that archived FFPE clinical specimens can be CLARITY-processed, immunostain

111 In clinical specimens, CASC15 levels increased during melan

112 tion of glycopeptides and phosphopeptides in clinical specimens, cell lysates, and mouse liver tissue

113 In clinical specimens, co-expression of various elements of

114 distributed multi-omic digitization of large clinical specimen cohorts across multiple sites as a pre

115 pathogenesis of pneumococcal pneumonia using clinical specimens collected for pneumonia surveillance

116 B card (BN), were evaluated using 200 frozen clinical specimens collected from January 2011 to June 2

117 wn titers and whole-blood, plasma, and urine clinical specimens collected from persons diagnosed with

118 virus genome sequences and metadata from 151 clinical specimens collected in Nashville, TN, from 2011

119 For analysis of clinical specimens, ColoType was also implemented with t

120 leic acid and 82.1% evaluated on unextracted clinical specimens compared to a validated real-time PCR

121 nd 3 (m1 and m3) are highly expressed in PCa clinical specimens compared with all other cancer types,

122 ty of the MTB-ISAD assay to detect MTB in 42 clinical specimens, confirming that the MTB-ISAD assay i

123 In clinical specimens, constant and variable quantification

124 me, using molecular enrichment methods, from clinical specimens containing low virus titers.

125 Ferret reference antisera were raised using clinical specimens containing viruses representing recen

126 tion decreased growth of PrCa cell lines and clinical specimen cultured ex vivo.

127 inoma (NSCLC) cell lines, animal models, and clinical specimens demonstrates that suppression of SMAD

128 racterize a collection of low-passage-number clinical-specimen-derived N. gonorrhoeae isolates for Op

129 rapidly catalog the bacterial composition of clinical specimens directly from patients, without need

130 3B were coordinately induced in HPV-positive clinical specimens during cancer progression, likely thr

131 dent on the detection of SARS-CoV-2 RNA from clinical specimens (e.g., nasopharyngeal swabs).

132 In clinical specimens, early-stage tumors that included >5%

133 In clinical specimens, elevated LAMB3 expression correlated

134 elucidated the antigenic characteristics of clinical specimens, enabling direct characterization of

135 ouble minute chromosomes in more than 20% of clinical specimens examined, a frequency consistent with

136 roteomic data relies upon the quality of the clinical specimens examined.

137 ns with 100% accuracy and, based on > 60,000 clinical specimens, exceeded the performance of current

138 rsity of drug sensitivities, with 70% of the clinical specimens exhibiting hypersensitivity to one or

139 For three clinical specimens, false negativity of the gold standar

140 From these samples, six clinical specimens (five blood, one synovial fluid) yiel

141 richment of CD133(hi)/ER(lo) cancer cells in clinical specimens following neoadjuvant endocrine thera

142 atory closed, the site handled close to 6000 clinical specimens for Ebola virus diagnosis and support

143 equence obtained directly from an unpassaged clinical specimen from a hospitalized infant.

144 me and conventional molecular approaches for clinical specimens from 1,051 patients submitted to the

145 Validation was conducted with clinical specimens from 397 asymptomatic donors from Mya

146 HIV-1 non-subtype B-infected clinical specimens from Cameroon were then used to optim

147 The resulting POC assay was evaluated on 414 clinical specimens from Darwin, Australia and Cambodia.

148 variation of the MG192 gene among and within clinical specimens from different patients, MG192 sequen

149 Clinical specimens from dogs, cats, and horses were exam

150 nuclear cells (PBMC) from well-characterized clinical specimens from HIV-1-infected individuals on an

151 ular characterization of viruses detected in clinical specimens from human cases revealed the presenc

152 esence and accessibility of this receptor in clinical specimens from index patients.

153 piratory viral pathogens or with 336 diverse clinical specimens from non-MERS-CoV cases; specimens fr

154 evaluated detailed immunological aspects in clinical specimens from non-small cell lung cancer (NSCL

155 Data on Salmonella isolated from various clinical specimens from patients from across The Gambia

156 In clinical specimens from patients receiving riluzole, we

157 ith cardiovascular disease in foam cells and clinical specimens from patients with AS.

158 Archived clinical specimens from patients with confirmed DENV, JE

159 nt between FilmArray and qRT-PCR results for clinical specimens from patients with EVD were 85% (23/2

160 , supernatant of infected cell cultures, and clinical specimens from patients with EVD.

161 The expression of target genes in clinical specimens from patients with lung cancer was ex

162 ortantly, such PMN-derived exosomes exist in clinical specimens from subjects with COPD but not healt

163 l isolates suspicious for B. pseudomallei or clinical specimens from suspected melioidosis cases.

164 ions specific to bacteria derived from human clinical specimens from the calendar years 2012 through

165 ne sequencing studies on stored ICV-positive clinical specimens from the two outbreaks have shown tha

166 Analysis of clinical specimens further showed that XPO5 phosphorylat

167 rdance with the expected results, and pooled clinical specimens had standard deviations and coefficie

168 ect detection of Aspergillus nucleic acid in clinical specimens has the potential to improve the diag

169 genomic analyses and expression profiling of clinical specimens have shaped much of our understanding

170 n differential expression in a panel of PDAC clinical specimens, highlighting its potential as a biom

171 and isolation of the mold in the culture of clinical specimens; however, antigen detection has provi

172 acteria, fungi, viruses, and/or parasites in clinical specimens; however, little data exist to guide

173 itive, HPV18 positive, or HPV45 positive) or clinical specimens (HPV16, -18, -31, -33/58, -45, or -52

174 y of cervical squamous cell carcinoma (CSCC) clinical specimens identified upregulation of miR-221-3p

175 with high titers, and for isolating VZV from clinical specimens.IMPORTANCE Varicella-zoster virus (VZ

176 f the microfilariae and their infrequency in clinical specimens in settings of endemicity present cha

177 Microbiology specimens are unique among clinical specimens in that optimal analysis may require

178 fication of >100 Lactobacillus isolates from clinical specimens in the context of presumed pathogenic

179 quencing (HTS) provides the means to analyze clinical specimens in unprecedented molecular detail.

180 RNA quality and provide excellent data from clinical specimens including formalin-fixed paraffin-emb

181 expansion of a variety of human tissues and clinical specimens, including paraffin-embedded, fresh f

182 The DNA sample were collected from clinical specimens, including sputum and blood hemocultu

183 In pilot studies on primary clinical specimens, including sputum, blood cultures, an

184 Furthermore, in clinical specimens, increased UBE3A levels correlated wi

185 ance, complete membrane proteome coverage of clinical specimen is usually hindered by the requirement

186 er chemotherapy, an observation confirmed in clinical specimens isolated longitudinally from a patien

187 Further, in clinical specimens, levels of Enpp1 were significantly e

188 Using clinical specimen material, we show reassortment between

189 In clinical specimens (n = 1041), increased expression of E

190 Decreased GATA4 level in clinical specimens negatively correlates with WNT7B or T

191 ital-acquired adenovirus identified from any clinical specimen (NICU patient or employee) or compatib

192 er, phospho-Akt levels are increased in most clinical specimens obtained from EGFR-mutant non-small-c

193 nd accurate detection of all IAV subtypes in clinical specimens of animal origin.

194 of eosinophils and IgE-coated mast cells in clinical specimens of BIA-ALCL.

195 In clinical specimens of breast cancer, reduced expression

196 in vitro along with tumor growth in vivo In clinical specimens of breast cancer, the absence of LMW-

197 he tumor suppressor genes DYRK1A and PTEN In clinical specimens of breast cancer, the expression of T

198 In clinical specimens of breast cancer, the presence of MDS

199 In clinical specimens of breast cancer, TRIB1 levels correl

200 In clinical specimens of breast cancer, we confirmed the pr

201 In clinical specimens of breast cancer, we established that

202 In clinical specimens of cancer, a strong correlation exist

203 In clinical specimens of cancer, less vascularized tumors e

204 associated vascular endothelial cells in the clinical specimens of ccRCC.

205 In clinical specimens of cervical cancer, we confirmed that

206 Investigations in clinical specimens of chemoresistant EOC tissues confirm

207 In clinical specimens of colorectal cancer, miR-15a levels

208 In clinical specimens of endometrial adenocarcinoma, PME-1

209 In clinical specimens of glioblastoma multiforme, elevated

210 In clinical specimens of glioblastoma multiforme, we found

211 ke membrane protein DCBLD2 is upregulated in clinical specimens of glioblastomas and head and neck ca

212 In clinical specimens of glioma, HSP90 was upregulated in t

213 In clinical specimens of HCC, we observed S100P overexpress

214 In clinical specimens of head and neck cancer, we found tha

215 In clinical specimens of human breast cancer, elevated leve

216 In clinical specimens of human glioblastoma, elevated level

217 lts from tumor and adjacent normal tissue in clinical specimens of human head and neck squamous carci

218 In clinical specimens of lung adenocarcinoma, low KLF10 exp

219 In clinical specimens of metastatic melanoma, we observed s

220 tial proteomics of fibroblasts isolated from clinical specimens of NFPAs with or without bone destruc

221 In clinical specimens of non-small cell lung cancer, we fou

222 ngly negative association with metastasis in clinical specimens of non-small cell lung cancer.

223 In clinical specimens of NSCLC with activating mutations of

224 High HOXA9 expression in clinical specimens of ovarian cancer was strongly associ

225 onocytes and with longer patient survival in clinical specimens of ovarian cancer.

226 th NF-kappaB activation and disease stage in clinical specimens of ovarian cancer.

227 Analysis of clinical specimens of PDAC showed that those with low SL

228 In clinical specimens of primary breast cancer or metastati

229 Galectin-4 expression in clinical specimens of prostate cancer correlated with po

230 Based on expression analysis performed on clinical specimens of salivary cancers, we identified in

231 In clinical specimens of TNBC, elevated expression of TDO2

232 ited overlapping subcellular localization in clinical specimens of triple-negative breast carcinoma.

233 In clinical specimens of various human cancers, there was a

234 l-in-one device was successfully used with 5 clinical specimens of zika and dengue virus from real pa

235 ecently been used to identify pathogens from clinical specimens or after culture within about 6 h.

236 organisms can be seen upon Gram staining of clinical specimens or can be isolated as the predominant

237 nusual or unexpected pathogens directly from clinical specimens, particularly when samples have been

238 only 11 of 24 (45.8%; 95% CI, 27.9 to 64.9) clinical specimens positive for adenovirus by real-time

239 In UCB clinical specimens, positive correlations in the express

240 peline was challenged using HTS data from 20 clinical specimens representative of those most often co

241 -based pathogen identification directly from clinical specimens requires time-consuming interpretatio

242 reference profiles were used to dissect bulk clinical specimens, revealing cell-type-specific phenoty

243 ression profiling of BIA-ALCL cell lines and clinical specimens reveals a predominantly type 17 helpe

244 In clinical specimens, RNLS expression in the tumor correla

245 of the melanoma secretome and validation in clinical specimens showed that the heparin-binding facto

246 nally, we extended these findings to primary clinical specimens, showing that SKN is frequently overe

247 chnical operational details, detection time, clinical specimen, status, the limit of detection/detect

248 determine the stability of galactomannan in clinical specimens stored at -20 degrees C that were pos

249 athogens needs to be performed directly from clinical specimens, such as cerebrospinal fluid (CSF), b

250 This small subset of patients and clinical specimens suggests that evolution of resistance

251 Retrospectively selected clinical specimens tested by a commercial reference labo

252 tection of galactomannan requires the use of clinical specimens that have been stored frozen.

253 Among clinical specimens the TBP demonstrated 100% sensitivity

254 The isolation of SARS-CoV-2 from nonlung clinical specimens, the detection of SARS-CoV-2 in autop

255 In clinical specimens, the expression of GD3S correlates wi

256 In clinical specimens, the expression of SOX2 and SOX9 corr

257 gene sequences obtained from IMD isolates or clinical specimens, the MenDeVAR Index provides rapid ev

258 For testing clinical specimens, the PSQ assay yielded a 98.4% sensit

259 In clinical specimens, there was an inverse relationship be

260 known species and the only one reported from clinical specimens thus far, being recovered mainly from

261 When mycobacteria are recovered in clinical specimens, timely species-level identification

262 isolates from retail meat products and human clinical specimens to assess their similarity based on a

263 method can reliably be implemented for many clinical specimens to directly genotype STEC and accurat

264 Further analyses of clinical specimens uncover a significant positive correl

265 Clinical specimens underwent routine processing with sub

266 ections by respiratory viruses isolated from clinical specimens using reconstituted human airway epit

267 proteotype data acquisition is feasible from clinical specimens using such standardized strategies.

268 We also found that increased CHOP mRNA in clinical specimens was a biomarker for poor outcomes in

269 The performance of the card on clinical specimens was evaluated with 1,050 blood sample

270 By using human clinical specimens, we also showed that miR-152 expressi

271 Using H. pylori isolates from 42 clinical specimens, we compared phenotypic and whole-gen

272 Extending these findings in clinical specimens, we documented an increase in TGF-bet

273 E)/Pten(-/-)/TPO-Cre tumor cells in vitro In clinical specimens, we found COL1A1 and LOX to be upregu

274 In clinical specimens, we found that expression levels of K

275 nd, in order to facilitate identification of clinical specimens, we have studied a set of clinical an

276 several preclinical tumor models as well as clinical specimens, we identified a mechanism whereby CD

277 In human clinical specimens, we observed an increase in megakaryo

278 els, cell line-based functional studies, and clinical specimens, we show that cyclin D1/CDK4 mediate

279 of the LSG-qPCR amplicons from reference and clinical specimens, we were able to differentiate four g

280 tained from M. tuberculosis culture-positive clinical specimens were also tested by Xpert at both rat

281 s Trichoderma isolated from human and animal clinical specimens were characterized morphologically an

282 ously typed HAdV field isolates and positive clinical specimens were correctly characterized by the t

283 olates representing 43 genera recovered from clinical specimens were evaluated.

284 Clinical specimens were obtained from a subset of these

285 Clinical specimens were obtained from multiple centres:

286 A total of 130 clinical isolates and 129 clinical specimens were studied.

287 Nonviable isolates and culture-negative clinical specimens were tested for the lytA gene and, if

288 ommon anatomical sites of isolation in human clinical specimens were the respiratory tract (40%), fol

289 Primary clinical specimens were used to develop the assay and th

290 V genomes from different sample types (e.g., clinical specimens) were generated and sequenced using t

291 validated for testing clinical isolates and clinical specimens, which improves the turnaround time f

292 indirectly from multiple tests on peripheral clinical specimens, which may have imperfect and uncerta

293 routine next-generation sequencing (NGS) on clinical specimens will improve the capabilities of clin

294 nd de novo assemble N. meningitidis DNA from clinical specimens with low bacterial loads.

295 s with confirmed antigenemia versus those in clinical specimens with no antigen.

296 We report the first evaluation of clinical specimens with REFtb assays in comparison to th

297 Excellent specificity was observed among clinical specimens with serologic or molecular markers f

298 d geographic clustering of HTNV strains from clinical specimens with the HTNV strains circulating in

299 iagnosing a panel of 13 bacterial species in clinical specimens within 2 h.

300 Sequencing pathogens directly from a primary clinical specimen would help circumvent the need for cul